About Us

About Us

DiNAQOR is a life sciences platform company that is pioneering proprietary human-based tissue drug development and technology to enable organ-specific delivery of gene therapies and other therapeutics. We were founded by a team of leading pharmaceutical and biotechnology executives and academics with deep R&D and gene therapy expertise. Our company is headquartered in the Greater Zurich Area, Switzerland, with additional presence in Laguna Hills, California and  Hamburg, Germany.

DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure.

We were founded in April 2019 by a team of leading pharmaceutical and biotechnology executives and academics with deep cardiology and gene therapy expertise. We have established partnerships and collaborations with leading institutions and companies including Lonza and University Medical Center Hamburg-Eppendorf to advance our cardiac gene therapy platform and pipeline. Our company is headquartered in Pfäffikon, Switzerland, with additional presence in London, England and Boston, Massachusetts.